Robert J. Motzer, MD | Authors


Risk Scoring Systems for Metastatic RCC

March 17, 2021

Considerations regarding the value of using the IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) criteria to risk-stratify patients with metastatic renal cell carcinoma as novel therapies become more widely used.

The Phase 3 CLEAR Study in Metastatic RCC

March 17, 2021

Robert J. Motzer, MD, of the Memorial Sloan Kettering Cancer Center, discusses the rationale for studying lenvatinib plus pembrolizumab or everolimus for frontline metastatic renal cell carcinoma treatment and reacts to outcomes of the phase 3 CLEAR study as presented at ASCO GU 2021.

Frontline Combination Approaches for Metastatic RCC

March 17, 2021

Toni Choueiri, MD, of the Dana-Farber Cancer Institute, comments on the impact of emerging data presented on newer, novel combination therapies as upfront treatment for patients with metastatic renal cell carcinoma.

Robert J. Motzer, MD, on the Possible Impact of a Phase 3 Trial for Advanced ccRCC

March 07, 2021

The medical oncologist at Memorial Sloan Kettering Cancer Center explained how this trial of MK-6482 plus lenvatinib versus cabozantinib in patients with advanced clear cell renal cell carcinoma could possibly improve the standard of care in this setting.